切除不能悪性黒色腫を有する日本患者を対象としたヤーボイ®の市販後調査

基本情報

NCT ID

NCT02717364

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

556

治験依頼者名

Bristol-Myers Squibb

概要

This study is a local, prospective, non-interventional, non-controlled, multicenter, observational study (regulatory postmarketing surveillance). Each physician will enroll patients who have received at least 1 dose of Yervoy, and each patient will be followed for up to 12 months. All patients will be evaluated for safety and effectiveness during Yervoy use (4 doses) and for 12 months from the first dose of Yervoy to confirm the safety profile of Yervoy under routine, daily practice

対象疾患

依頼者（Sponsor）